We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+16.2%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$126M
AUM Growth
+$27.3M
Cap. Flow
+$10M
Cap. Flow %
7.93%
Top 10 Hldgs %
54.03%
Holding
70
New
10
Increased
16
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.68M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$3.29M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$2.09M
4
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
+$1.56M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$1.51M

Top Sells

Rank Stock Value
1
XNPT
XENOPORT, INC.
XNPT
+$1.04M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$1.04M
3
BSTC
BioSpecifics Technologies Corp.
BSTC
+$1.01M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$683K
5
VCEL icon
Vericel Corp
VCEL
+$681K

Sector Composition

Rank Sector Weight
1 Healthcare 73.53%
2 Miscellaneous 25.55%
3 Financials 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$13.6M 10.73%
110,928
– –
ATRC icon
2
AtriCure
ATRC
$2.47B
$13.2M 10.44%
661,331
+62,448
+10% +$1.07M
ASPX
3
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$7.13M 5.64%
135,885
-16,117
-11% -$473K
NXTM
4
DELISTED
NxStage Medical Inc.
NXTM
$6.89M 5.45%
384,154
– –
WINT
5
DELISTED
Windtree Therapeutics Inc
WINT
$6.61M 5.23%
407,053
– –
PODD icon
6
Insulet
PODD
$10.1B
$5.04M 3.99%
109,418
– –
NVDQ
7
DELISTED
Novadaq Technologies Inc.
NVDQ
$4.38M 3.46%
263,541
– –
OCRX
8
DELISTED
Ocera Therapeutics, Inc.
OCRX
$4.04M 3.2%
634,893
-40,757
-6% -$238K
AERI
9
DELISTED
Aerie Pharmaceuticals
AERI
$3.87M 3.06%
132,442
-12,900
-9% -$327K
DSCI
10
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$3.58M 2.83%
384,794
– –
ICPT
11
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.42M 2.7%
21,900
+19,900
+995% +$3.68M
CTIC
12
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$3.36M 2.66%
+142,500
New +$3.29M
PLX icon
13
Protalix BioTherapeutics
PLX
$205M
$2.55M 2.01%
138,389
+9,545
+7% +$205K
ACHN
14
DELISTED
Achillion Pharmaceuticals
ACHN
$2.42M 1.91%
197,500
+171,500
+660% +$2.09M
BEAT
15
DELISTED
BioTelemetry, Inc.
BEAT
$2.36M 1.87%
235,645
– –
STXS icon
16
Stereotaxis
STXS
$145M
$2.04M 1.61%
1,718,719
– –
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$2.51B
$2.03M 1.6%
166,656
+90,256
+118% +$997K
MASI
18
DELISTED
Masimo
MASI
$1.78M 1.41%
67,500
+50,000
+286% +$1.23M
RIGL icon
19
Rigel Pharmaceuticals
RIGL
$868M
$1.7M 1.34%
+74,907
New +$1.51M
MTEM
20
DELISTED
Molecular Templates, Inc.
MTEM
$1.69M 1.34%
3,218
-151
-4% -$75.5K
TRVN
21
DELISTED
Trevena, Inc.
TRVN
$1.67M 1.32%
+448
New +$1.48M
SPNC
22
DELISTED
Spectranetics Corp
SPNC
$1.46M 1.15%
42,162
– –
EVFM
23
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$1.4M 1.1%
+2,072
New +$1.56M
CLVS
24
DELISTED
Clovis Oncology, Inc.
CLVS
$1.34M 1.06%
23,900
-13,000
-35% -$683K
BSTC
25
DELISTED
BioSpecifics Technologies Corp.
BSTC
$1.29M 1.02%
33,466
-26,588
-44% -$1.01M
1
2 3

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, DAFNA Capital Management held 70 positions worth $126M, up 27% from $99.1M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

DAFNA Capital Management deployed $10M of net new capital in Q4 2014, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was CTI BioPharma Corp. (DE) Common Stock: 142,500 shares worth $3.36M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 75% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was XENOPORT, INC., an estimated $1.04M trimmed.

  • DAFNA Capital Management's largest Q4 2014 buy was CTI BioPharma Corp. (DE) Common Stock: 142,500 shares worth $3.36M.
  • DAFNA Capital Management added most to Intercept Pharmaceuticals, Inc. in Q4 2014, an estimated $3.68M increase.
  • DAFNA Capital Management's biggest Q4 2014 reduction was XENOPORT, INC., cutting an estimated $1.04M.
  • DAFNA Capital Management fully exited Neurocrine Biosciences in Q4 2014, selling an estimated $1.04M.
  • DAFNA Capital Management's ten largest holdings make up 54% of its $126M portfolio in Q4 2014.
  • DAFNA Capital Management opened 10 new positions and closed 7 in Q4 2014.
  • DAFNA Capital Management's portfolio value rose 27% quarter-over-quarter to $126M.

Based on DAFNA Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.